Lakhmir Chawla
About Lakhmir Chawla
Lakhmir Chawla, M.D., is the CEO of Stavro Medical and a recognized expert in acute kidney injury and shock, with a distinguished career in medical research and leadership.
Current Role as CEO of Stavro Medical
Lakhmir Chawla, M.D., currently serves as the Chief Executive Officer of Stavro Medical. In this role, he oversees the strategic and operational aspects of the company, working to advance its medical and business objectives. Stavro Medical focuses on leveraging innovative treatments to improve patient outcomes across various medical conditions.
Previous Position at Silver Creek Pharma
Prior to his current role, Lakhmir Chawla was the Chief Medical Officer at Silver Creek Pharma. He was responsible for the Acute Ischemic Stroke development program and led the initiation of the ARPEGGIO neuroprotection study. His tenure at Silver Creek Pharma involved strategic leadership and clinical oversight to drive advancements in stroke treatment.
Role as Chief Medical Officer at La Jolla Pharmaceutical Company
Lakhmir Chawla also served as the Chief Medical Officer at La Jolla Pharmaceutical Company. In this role, he oversaw the development and conduct of the Phase 3 ATHOS-3 trial, which focused on critically ill patients. His work contributed significantly to the company’s clinical research efforts.
Academic Career at George Washington University
Lakhmir Chawla held a prominent academic position as a Professor of Medicine at George Washington University. He had dual appointments in the Department of Anesthesiology and Critical Care Medicine, and the Department of Medicine, Division of Renal Diseases and Hypertension. His academic career was marked by significant contributions to medical education and research in these areas.
Expertise in Acute Kidney Injury
Lakhmir Chawla is an internationally renowned expert in the field of acute kidney injury (AKI) and shock. He has authored over 160 peer-reviewed publications and is an active investigator in the fields of AKI biomarkers, AKI risk prediction, AKI therapeutics, and chronic kidney disease caused by AKI. His research work has earned him significant recognition, including the International Vicenza Award for Critical Care Nephrology.